arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Gain Therapeutics, Inc.

GANX
$1.85 ▼ -0.10 (-5.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Gain Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $79.3M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -41.2%
FCF / Share $-0.11
Trailing P/E
Price / Book 7.1x
FCF Yield
Debt / Equity 0.03
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-4.68M
↑ +19.5%
FCF / Share Free cash flow per share
$-0.11
↑ +2.5%
Long-Term Debt Long-term obligations
$343.69K
↓ -8.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
8
Financial Health
91
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters